Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 10/2016

01-10-2016 | Original Paper

Substance Use Patterns of HIV-Infected Russian Women with and Without Hepatitis C Virus Co-infection

Authors: Jennifer L. Brown, Ralph J. DiClemente, Jessica M. Sales, Eve S. Rose, Polina Safonova, Olga S. Levina, Nikolay Belyakov, Vadim V. Rassokhin

Published in: AIDS and Behavior | Issue 10/2016

Login to get access

Abstract

Individuals with HIV and hepatitis C virus (HCV) co-infection may experience substance use related health complications. This study characterized substance use patterns between HIV/HCV co-infected and HIV mono-infected Russian women. HIV-infected women (N = 247; M age = 30.0) in St. Petersburg, Russia, completed a survey assessing substance use, problematic substance use, and the co-occurrence of substance use and sexual behaviors. Covariate adjusted logistic and linear regression analyses indicated that HIV/HCV co-infected participants (57.1 %) reported more lifetime drug use (e.g., heroin: AOR: 13.2, 95 % CI 4.9, 35.3, p < .001), problem drinking (β = 1.2, p = .05), substance use problems (β = 1.3, p = .009), and increased likelihood of past injection drug use (AOR: 26.4, 95 % CI 8.5, 81.9, p < .001) relative to HIV mono-infected individuals. HIV/HCV co-infection was prevalent and associated with increased substance use and problematic drug use. Findings highlight the need for ongoing substance use and HIV/HCV risk behavior assessment and treatment among HIV/HCV co-infected Russian women.
Literature
1.
UNAIDS. UNAIDS report on the global AIDS epidemic. 2010.
2.
Burruano L, Kruglov Y. HIV/AIDS epidemic in Eastern Europe: recent developments in the Russian Federation and Ukraine among women. Gend Med. 2009;6(1):277–89.PubMedCrossRef
3.
4.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.PubMedCrossRef
5.
Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S77–84.PubMedCrossRef
6.
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7.PubMedCrossRef
7.
Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection. Arch Intern Med. 2000;160:3365–73.PubMedCrossRef
8.
9.
Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 2006;41(10–12):1395–463.PubMedCrossRef
10.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.PubMedCrossRef
11.
Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction. 2006;101(2):252–66.PubMedCrossRef
12.
Spittal PM, Bruneau J, Craib KJP, Miller C, Lamothe F, Weber AE, et al. Surviving the sex trade: a comparison of HIV risk behaviors among street-involved women in two Canadian cities who inject drugs. AIDS Care. 2003;15(2):187.PubMedCrossRef
13.
Wood E, Schachar J, Li K, Stoltz J-A, Shannon K, Miller C, et al. Sex trade involvement is associated with elevated HIV incidence among injection drug users in Vancouver. Addict Res Theory. 2007;15(3):321–5.CrossRef
14.
Kozlov AP, Shaboltas AV, Toussova OV, Verevochkin SV, Masse BR, Perdue T, et al. HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia. AIDS. 2006;20:901–6.PubMedCrossRef
15.
Grieb S, Davey-Rothwell M, Latkin C. Concurrent sexual partnerships among urban African American high-risk women with main sex partners. AIDS Behav. 2012;16(2):323–33.PubMedPubMedCentralCrossRef
16.
Khan M, Berger A, Hemberg J, O’Neill A, Dyer T, Smyrk K. Non-injection and injection drug use and STI/HIV risk in the United States: the degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users. AIDS Behav. 2013;17(3):1185–94.PubMedPubMedCentralCrossRef
17.
Kuo I, Greenberg AE, Magnus M, Phillips G II, Rawls A, Peterson J, et al. High prevalence of substance use among heterosexuals living in communities with high rates AIDS of and poverty in Washington, DC. Drug Alcohol Depend. 2011;117(2–3):139–44.PubMedCrossRef
18.
Leigh BC, Ames SL, Stacy AW. Alcohol, drugs, and condom use among drug offenders: an event-based analysis. Drug Alcohol Depend. 2008;93(1–2):38–42.PubMedCrossRef
19.
20.
Wurst FM, Dursteler-MacFarland KM, Auwaerter V, Ergovic S, Thon N, Yegles M, et al. Assessment of alcohol use among methadone maintenance patients by direct ethanol metabolites and self-reports. Alcohol Clin Exp Res. 2008;32(9):1552–7.PubMedCrossRef
21.
22.
Noonan A, Kavanagh P, Sweeney B. Drug users’ failure to modify alcohol consumption in response to hepatitis C. Ir J Psychol Med. 2009;26(1):27–31.CrossRef
23.
Watson B, Conigrave KM, Wallace CJ, Whitfield JB, Wurst F, Haber PS. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug Alcohol Rev. 2007;26:231–9.PubMedCrossRef
24.
Palepu A, Cheng DM, Kim T, Nunes D, Vidaver J, Alperen J, et al. Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems. J Subst Abuse Treat. 2006;31:411–7.PubMedPubMedCentralCrossRef
25.
Krupitsky EM, Horton NJ, Williams EC, Lioznov D, Kuznetsova M, Zvartau E, et al. Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug Alcohol Depend. 2005;79(2):251–6.PubMedPubMedCentralCrossRef
26.
WHO. Global status report on alcohol and health 2011. Geneva: WHO; 2011.
27.
Shin SS, Mathew TA, Yanova GV, Fitzmaurice GM, Livchits V, Yanov SA, et al. Alcohol consumption among men and women with tuberculosis in Tomsk, Russia. Cent Eur J Public Health. 2010;18(3):132–8.PubMedPubMedCentral
28.
Baliunas D, Rehm J, Irving H, Shuper P. Alcohol consumption and risk of incident human immunodeficiency virus infection: a meta-analysis. Int J Public Health. 2010;55(3):159–66.PubMedCrossRef
29.
Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal considerations on alcohol and HIV/AIDS—a systematic review. Alcohol Alcohol. 2010;45(2):159–66.PubMedCrossRef
30.
Donovan C, McEwan R. A review of the literature examining the relationship between alcohol use and HIV-related sexual risk-taking in young people. Addiction. 1995;90(3):319–28.PubMedCrossRef
31.
Griffin JA, Umstattd MR, Usdan SL. Alcohol use and high-risk sexual behavior among collegiate women: a review of research on alcohol myopia theory. J Am Coll Health. 2010;58(6):523–32.PubMedCrossRef
32.
Shuper PA, Joharchi N, Irving H, Rehm J. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: review and meta-analysis. AIDS Behav. 2009;13(6):1021–36.PubMedCrossRef
33.
34.
Abdala N, Grau LE, Zhan W, Shaboltas AV, Skochilov RV, Kozlov AP, et al. Inebriation, drinking motivations and sexual risk taking among sexually transmitted disease clinic patients in St. Petersburg, Russia. AIDS Behav. 2013;17(3):1144–50.PubMedCrossRef
35.
Abdala N, White E, Toussova OV, Krasnoselskikh TV, Verevochkin S, Kozlov AP, et al. Comparing sexual risks and patterns of alcohol and drug use between injection drug users (IDUs) and non-IDUs who report sexual partnerships with IDUs in St. Petersburg, Russia. BMC Public Health. 2010. doi:10.​1186/​1471-2458-10-676.PubMedPubMedCentral
36.
Somlai AM, Kelly JA, Benotsch E, Gore-Felton C, Ostrovski D, McAuliffe TL, et al. Characteristics and predictors of HIV risk behaviors among injection-drug-using men and women in St. Petersburg, Russia. AIDS Educ Prev. 2002;14(4):295–305.PubMedCrossRef
37.
Heimer R, Eritsyan K, Barbour R, Levina OS. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infect Dis. 2014;14 Suppl 6:S12-S.CrossRef
38.
Degenhardt L, Mathers BM, Wirtz AL, Wolfe D, Kamarulzaman A, Carrieri MP, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int J Drug Policy. 2014;25(1):53–60.PubMedCrossRef
39.
Latt NC, Spencer JD, Beeby PJ, McCaughan GW, Saunders JB, Collins E, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000;15(2):175–81.PubMedCrossRef
40.
Mateu-Gelabert P, Guarino H, Jessell L, Teper A. Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City. J Subst Abuse Treat. 2015;48(1):13–20.PubMedCrossRef
41.
Cepeda JA, Niccolai LM, Eritsyan K, Heimer R, Levina O. Moderate/heavy alcohol use and HCV infection among injection drug users in two Russian cities. Drug Alcohol Depend. 2013;132(3):571–9.PubMedPubMedCentralCrossRef
42.
Bao Y-p DuC, H-y Lu, Lian Z, Yi M, S-y Yue Yan, et al. The Investigation of HIV and HCV infection and risk factors among opiate drug users in Beijing, China. Am J Drug Alcohol Abuse. 2012;38(2):140–5.PubMedCrossRef
43.
Batki SL, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment. Am J Addict. 2011;20(4):312–8.PubMedPubMedCentralCrossRef
44.
Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug Alcohol Depend. 2009;101(3):176–82.PubMedCrossRef
45.
Du J, Wang Z, Xie B, Zhao M. Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China. Am J Drug Alcohol Abuse. 2012;38(3):228–32.PubMedPubMedCentralCrossRef
46.
McCusker M. Influence of Hepatitis C status on alcohol consumption in opiate users in treatment. Addiction. 2001;96(7):1007–14.PubMedCrossRef
47.
Perlman DC, Jordan AE, McKnight C, Young C, Delucchi KL, Sorensen JL, et al. Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions. J Addict Dis. 2014;33(4):322–31.PubMedPubMedCentralCrossRef
48.
Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat. 2008;35:78–86.PubMedCrossRef
49.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption: II. Addiction. 1993;88(6):791–804.PubMedCrossRef
50.
Selin KH. Test-retest reliability of the alcohol use disorder identification test in a general population sample. Alcohol Clin Exp Res. 2003;27(9):1428–35.PubMedCrossRef
51.
52.
Gavin DR, Ross HE, Skinner HA. Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br J Addict. 1989;84(3):301–7.PubMedCrossRef
53.
Fromme K, Stroot E, Kaplan D. Comprehensive effects of alcohol: development and psychometric assessment of a new expectancy questionnaire. Psychol Assess. 1993;5(1):19–26.CrossRef
54.
IBM Corporation. IBM SPSS Statistics for Windows. 23.0 ed. Armonk, NY: IBM Corporation; 2015.
55.
Kruse GR, Barbour R, Heimer R, Shaboltas AV, Toussova OV, Hoffman IF, et al. Drug choice, spatial distribution, HIV risk, and HIV prevalence among injection drug users in St. Petersburg, Russia. Harm Reduct J. 2009. doi:10.​1186/​1477-7517-6-22.PubMedPubMedCentral
56.
Samet JH. Russia and human immunodeficiency virus—Beyond crime and punishment. Addiction. 2011;106(11):1883–5.PubMedCrossRef
57.
Krupitsky EM, Zvartau EE, Lioznov DA, Tsoy MV, Egorova VY, Belyaeva TV, et al. Co-Morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad region, Russia. Eur Addict Res. 2006;12(1):12–9.PubMedCrossRef
58.
Vlahov D, Robertson AM, Strathdee SA. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010;50(Suppl 3):S114–21.PubMedPubMedCentralCrossRef
59.
Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRef
60.
Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12):2053–9.PubMedPubMedCentralCrossRef
61.
Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59(1):17–31.PubMedCrossRef
62.
Brown JL, DeMartini KS, Sales JM, Swartzendruber AL, DiClemente RJ. Interventions to reduce alcohol use among HIV-infected Individuals: a review and critique of the literature. Curr HIV/AIDS Rep. 2013;10:356–70.PubMedCrossRef
63.
Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40(Suppl 5):S276–85.PubMedPubMedCentralCrossRef
64.
Calabrese SK, Burke SE, Dovidio JF, Levina OS, Uusküla A, Niccolai LM, et al. Internalized HIV and drug stigmas: Interacting forces threatening health status and health service utilization among people with HIV who inject drugs in St, Petersburg, Russia. AIDS Behav. 2015. doi:10.​1007/​s10461-015-1100-4.
Metadata
Title
Substance Use Patterns of HIV-Infected Russian Women with and Without Hepatitis C Virus Co-infection
Authors
Jennifer L. Brown
Ralph J. DiClemente
Jessica M. Sales
Eve S. Rose
Polina Safonova
Olga S. Levina
Nikolay Belyakov
Vadim V. Rassokhin
Publication date
01-10-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 10/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1362-5

Other articles of this Issue 10/2016

AIDS and Behavior 10/2016 Go to the issue

Original Paper

HIV and STI Testing and Related Factors Among Men Who Have Sex with Men in Estonia

Original Paper

A Multi-Group Latent Class Analysis of Chronic Medical Conditions Among Men Who Have Sex with Men

Original Paper

Barriers to Linkage to HIV Care in Ugandan Fisherfolk Communities: A Qualitative Analysis

Original Paper

The Road Less Travelled: Exploring Gay and Bisexual Men’s Explanations of ‘Uncommon’ Routes of HIV Transmission

Original Paper

Retaining HIV Patients in Care: The Role of Initial Patient Care Experiences

Original Paper

Sexual Orientation, Gender Identity and Perceived Source of Infection Among Men Who Have Sex with Men (MSM) and Transgender Women (TW) Recently Diagnosed with HIV and/or STI in Lima, Peru
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits